Biodesix Q2 EPS $(0.17) Beats $(0.21) Estimate, Sales $11.87M Beat $11.38M Estimate
Portfolio Pulse from vinayak@benzinga.com
Biodesix reported Q2 earnings per share of $(0.17), beating the analyst consensus estimate of $(0.21) by 19.05%. This is a 46.88% increase over losses from the same period last year. The company also reported quarterly sales of $11.87 million, beating the analyst consensus estimate of $11.38 million by 4.32%. This is an 8.42% increase over sales from the same period last year.
August 07, 2023 | 8:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biodesix's Q2 earnings and sales beat analyst estimates, showing significant YoY growth. This could positively impact the company's stock in the short term.
Biodesix's better-than-expected Q2 earnings and sales, along with significant YoY growth, indicate strong financial performance. This is likely to be viewed positively by investors, potentially leading to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100